Eye Drop

As the myopia epidemic continues to expand and affect children, management of the condition remains a source of discussion among ophthalmologists.

WASHINGTON — In this Healio Video Perspective from Eyecelerator@ASCRS, Ben Bergo, CEO of Visus Therapeutics, discusses the results of the VIVID phase 2 study of presbyopia drop formulations in patients with emmetropic presbyopia.

More options are on the way to treat patients with presbyopia, according to a presentation at Real World Ophthalmology.

Orasis Pharmaceuticals announced that its phase 3 trials showed patients treated with CSF-1 achieved a statistically significant three-line or more gain in distance-corrected near visual acuity with no loss of distance visual acuity.

The FDA approved Lastacaft antihistamine eye drops switching from prescription to over-the-counter treatment, and a North Carolina clinician shared with Healio how she has been recommending it in her practice.

The FDA approved the first pharmacological drug for the treatment of presbyopia in October 2021. Vuity from Allergan is a once-daily 1.25% pilocarpine HCL ophthalmic solution with pHast technology.

They said it would never happen. We would never see it in our lifetimes. It was a dream held by millions, but sadly, naught but a pipe dream.

At the virtual European Society of Cataract and Refractive Surgeons winter meeting, A. John Kanellopoulos, MD, speaks about mini-PRK.

In the field of ophthalmology and optometry, dry eye disease has been anything but delightful, fun or mesmerizing.

Welcome to another edition of CEDARS/ASPENS Debates. CEDARS/ASPENS is a society of cornea, cataract and refractive surgery specialists, here to discuss some of the latest hot topics in ophthalmology.